We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Form 483 Provides Insight into FDA’s Rejection of HIV Drugs
Gilead Form 483 Provides Insight into FDA’s Rejection of HIV Drugs
May 30, 2013
A Form 483 posted by the FDA late Wednesday highlights the quality deficiencies that led agency reviewers to reject Gilead Science’s applications for a pair of HIV treatments.